<DOC>
	<DOCNO>NCT00869557</DOCNO>
	<brief_summary>The objective double-blinded , multicenter , randomize , active-controlled study evaluate safety efficacy Stribild , single-tablet regimen ( STR ) contain fix dos elvitegravir ( EVG ) /GS-9350 ( cobicistat ; COBI ) /emtricitabine ( FTC ) /tenofovir disoproxil fumarate ( TDF ) versus efavirenz ( EFV ) /FTC/TDF ( Atripla ) HIV-1 infect , antiretroviral treatment-naive adult participant . Stribild offer alternative STR patient candidate non-nucleoside reverse transcriptor ( NNRTI ) -based STRs . Participants randomize 2:1 ratio receive Stribild Atripla . Randomization stratify HIV-1 RNA level ( ≤ 100,000 copies/mL &gt; 100,000 copies/mL ) screening . After Week 48 , participant continue take blind study drug attend visit every 12 week treatment assignment unblinded ( Week 60 ) , point participant attend Unblinding Visit give option participate open-label rollover extension ( extension schedule open Stribild become commercially available , Gilead Sciences elect terminate study ) .</brief_summary>
	<brief_title>Study Safety Efficacy Stribild Versus Atripla Human Immunodeficiency Virus , Type 1 ( HIV-1 ) Infected , Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Plasma HIV1 RNA level ≥ 5,000 copies/mL No prior use approved experimental antiHIV drug Normal electrocardiogram ( ECG ) Adequate renal function : estimate glomerular filtration rate ≥ 80 mL/min accord CockcroftGault formula Hepatic transaminases ≤ 2.5 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function Cluster determinant 4 ( CD4 ) cell count &gt; 50 cells/µL Serum amylase ≤ 1.5 x ULN Normal thyroidstimulating hormone Negative serum pregnancy test ( female childbearing potential ) Males females childbearing potential must agree utilize highly effective contraception method screen throughout duration study treatment 12 week follow last dose study drug Life expectancy ≥ 1 year Ability understand sign write informed consent form New acquire immunodeficiency syndrome ( AIDS ) define condition diagnose within 30 day prior screen Documented drug resistance nucleoside reverse transcriptase inhibitor nonnucleoside reverse transcriptase inhibitor primary protease inhibitor resistance mutation ( ) Hepatitis B surface antigen positive Hepatitis C antibody positive Participants experience cirrhosis Participants experience ascites Participants experience encephalopathy Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Vaccinated within 90 day study dose History family history Long QT Syndrome family history sudden cardiac death unexplained death otherwise healthy individual age 30 Presence history cardiovascular disease , cardiomyopathy , and/or cardiac conduction abnormality Prolonged QTcF interval screen PR interval ≥ 200 msec ≤ 120 msec ECG screen QRS ≥ 120 msec ECG screening Implanted defibrillator pacemaker Participants receive ongoing therapy disallow medication Current alcohol substance use judge potentially interfere participant study compliance History ongoing malignancy ( include untreated carcinoma situ ) cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Participation clinical trial without prior approval Medications contraindicate use EFV , EVG , COBI , FTC , TDF Any known allergy excipients Atripla Stribild tablets Any clinical condition prior therapy would make participant unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Antiretroviral Treatment-Naive</keyword>
	<keyword>treatment naive</keyword>
</DOC>